{"id":11336,"date":"2023-11-20T10:54:00","date_gmt":"2023-11-20T02:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11336"},"modified":"2024-11-05T10:57:13","modified_gmt":"2024-11-05T02:57:13","slug":"baheal-pharmaceutical-group-enters-commercialization-partnership-with-guangdong-ruidio-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11336","title":{"rendered":"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology"},"content":{"rendered":"\n

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio\u2019s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT. These products will be exclusively promoted and marketed by Baheal upon regulatory approval in mainland China. The partnership is set to continue until December 31, 2033, with Ruidio paying Baheal service fees throughout the cooperation period.<\/p>\n\n\n\n

Significance of Ruidio’s Radiopharmaceuticals and Imaging Equipment<\/strong>
99mTc-3PRGD2, a radioactive drug conjugate (RDC) targeting integrin, is the first Category 1 drug for nuclear medicine radiation diagnosis in China and the world’s first broad-spectrum tumor imaging agent for SPECT imaging. It has the ability to target integrin in tumor neovascularization \u03b1v\u03b23 receptors, allowing for earlier and more accurate diagnosis of benign, malignant, and lymph node metastasis of tumor tissue. Other products in Ruidio’s pipeline, such as 99mTc HP Ark2 for screening HER2 positive tumor patients and guiding treatment, 99mTc POFAP for SPECT imaging, and medical imaging SPECT-CT series devices, are yet to enter clinical trials.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[288,16,1925],"class_list":["post-11336","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-baheal-pharmaceutical","tag-cancer","tag-ruidio-technology"],"yoast_head":"\nBaheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio\u2019s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT. These products will be exclusively promoted and marketed by Baheal upon regulatory approval in mainland China. The partnership is set to continue until December 31, 2033, with Ruidio paying Baheal service fees throughout the cooperation period.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11336\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11336\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-20T02:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T02:57:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11336#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11336\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology\",\"datePublished\":\"2023-11-20T02:54:00+00:00\",\"dateModified\":\"2024-11-05T02:57:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11336\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Baheal Pharmaceutical\",\"Cancer\",\"Ruidio Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11336#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11336\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11336\",\"name\":\"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-20T02:54:00+00:00\",\"dateModified\":\"2024-11-05T02:57:13+00:00\",\"description\":\"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio\u2019s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT. These products will be exclusively promoted and marketed by Baheal upon regulatory approval in mainland China. The partnership is set to continue until December 31, 2033, with Ruidio paying Baheal service fees throughout the cooperation period.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11336#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11336\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11336#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology - Insight, China's Pharmaceutical Industry","description":"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio\u2019s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT. These products will be exclusively promoted and marketed by Baheal upon regulatory approval in mainland China. The partnership is set to continue until December 31, 2033, with Ruidio paying Baheal service fees throughout the cooperation period.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11336","og_locale":"en_US","og_type":"article","og_title":"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11336","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-20T02:54:00+00:00","article_modified_time":"2024-11-05T02:57:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11336#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11336"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology","datePublished":"2023-11-20T02:54:00+00:00","dateModified":"2024-11-05T02:57:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11336"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Baheal Pharmaceutical","Cancer","Ruidio Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11336#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11336","url":"https:\/\/flcube.com\/?p=11336","name":"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-20T02:54:00+00:00","dateModified":"2024-11-05T02:57:13+00:00","description":"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio\u2019s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT. These products will be exclusively promoted and marketed by Baheal upon regulatory approval in mainland China. The partnership is set to continue until December 31, 2033, with Ruidio paying Baheal service fees throughout the cooperation period.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11336#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11336"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11336#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11336"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11336\/revisions"}],"predecessor-version":[{"id":11337,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11336\/revisions\/11337"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}